Proteomics is more than just generating lists of proteins that increase or decrease in expression as a cause or consequence of pathology. The goal should be to characterize the information flow through the intercellular protein circuitry which communicates with the extracellular microenvironment and then ultimately to the serum/plasma macroenvironment. The nature of this information can be a cause, or a consequence, of disease and toxicity based processes as cascades of reinforcing information percolate through the system and become reflected in changing proteomic information content of the circulation. Serum Proteomic Pattern Diagnostics is a new type of proteomic platform in which patterns of proteomic signatures from high dimensional mass spectrometry data are used as a diagnostic classifier. While this approach has shown tremendous promise in early detection of cancers, detection of drug-induced toxicity may also be possible with this same technology. Analysis of serum from rat models of anthracycline and anthracenedione induced cardiotoxicity indicate the potential clinical utility of diagnostic proteomic patterns where low molecular weight peptides and protein fragments may have higher accuracy than traditional biomarkers of cardiotoxicity such as troponins. These fragments may one day be harvested by circulating nanoparticles designed to absorb, enrich and amplify the diagnostic biomarker repertoire generated even at the critical initial stages of toxicity.
Adam, B.L., Qu, Y., Davis, J.W., Ward, M.D., Clements, M.A., Cazares, L.H., Semmes, O.J., Schellhammer, P.F., Yasui, Y., Feng, Z., and Wright, Jr. G.L. (2002). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res62(13), 3609—14.
2.
Alderton, P.M., Gross, J., and Green, M.D. (1992). Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529). Cancer Res52(1), 194—201.
3.
Anderson, N.L., and Anderson, N.G. (2002). The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics11, 845— 67.
4.
Bristow, M.R., Mason, J.W., Billingham, M.E., and Daniels, S.R. (1981). Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J102, 709—18.
5.
Cojocel, C., Maita, K., Baumann, K., and Hook, J.B. (1984). Renal processing of low molecular weight proteins . Pflugers Arch401(4), 333—9.
6.
Conrads, T.P., Zhou, M., Petricoin, E.F. III , Liotta, L., and Veenstra, T.D. (2003). Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn3(4), 411—20.
7.
Ewer, M.S., Gibbs, H.R., Swafford, J., and Benjamin, R.S. (1999). Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?Semin Oncol26(suppl. 12), 96—101.
8.
Hasinoff, B.B., Hellmann, K., Herman, E.H., and Ferrans, V.J. (1998). Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem5(1), 1—28.
9.
Hasinoff, B.B., Schnabl, K.L., Marusak, R.A., Patel, D., and Huebner, E. (2003). Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol3(2), 89—99.
10.
Herman, E.H., and Ferrans, V.J. (1998). Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol25(Suppl 10), 15—21.
11.
Herman, E.H., Zhang, J., Rifai, N., Lipshultz, S.E., Hasinoff, B.B., Chadwick, D.P., Knapton, A., Chai, J., and Ferrans, V.J. (2001). The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol48(4), 297—304.
12.
Hingorani, S.R., Emanuel, F., Petricoin, E.F., III , Maitra, A., Rajapakse, V., King , C., Jacobetz, M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A., Kawaguchi, Y., Zhou, Y., Johann, D., Liotta, L.A., Crawford, H.C., Putt, M.E., Jacks, T., Konieczny, S.F., Wright, C.E., Hruban, R.E., Lowry, A.M., and Tuveson D . A. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell10, 6—21.
13.
Holland, J. H., ed. (1994). Adaptation in Natural and Artificial Systems: an Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence, 3rd ed., MIT PressCambridge, Massachusetts.
Kohonen, T. (1982). Self-organizing formation of topologically correct feature maps. Biol Cybernetics43, 59—69.
16.
Kohonen, T. (1990). The self-organizing map. Proc IEEE78, 1464—80.
17.
Lambertenghi-Deliliers G., Zanon, P.L., Pozzoli, E.F., and Bellini, O. (1976) Myocardial injury induced by a single dose of adriamycin: an electron microscopic study. Tumor62, 517—28.
18.
Li, J., Zhang, Z., Rosenzweig, J., Wang, Y.Y., and Chan, D.W. (2002). Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem48(8), 1296—304.
19.
Liotta, L.A., Ferrari, M., and Petricoin, E. (2003). Clinical proteomics: written in blood. Nature425, 905.
20.
Maack, T. (1975). Renal handling of low molecular weight proteins . Am J Med58(1), 57—64.
21.
McDonald, W.H., and Yates, J.R., III. (2002). Shotgun proteomics and biomarker discovery. Dis Markers18(2), 99—105.
22.
Mehta, A., Ross, S., Lowenthal, M.S., Fusaro, V.Fishman, D.A., Petricoin, E.F., and Liotta, L.A. (2003). Biomarker amplification by serum carrier protein binding. Disease Markers19, 1—10.
23.
Petricoin, E.F., III , Ardekani, A.M., Hitt, B.A., Levine , P.J., Fusaro, V.A., Steinberg, S.M., Mills, G.B., Simone, C., Fishman, D.A., Kohn, E.C., and Liotta, L.A. (2002a). Use of proteomic patterns in serum to identify ovarian cancer. Lancet359(9306), 572—7.
24.
Petricoin, E., III, and Liotta, L.A. (2003a). Counterpoint: the vision for a new diagnostic paradigm. Clin Chem49(8), 1276—1278.
25.
Petricoin, E.F., and Liotta, L.A. (2003b). Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. Clin Chem49(4), 533—4.
26.
Petricoin, E.F., III , Mills, G.B., Kohn, E.S., Liotta , L.A. (2002b). Proteomic patterns in serum and identification of ovarian cancer [Reply]. Lancet360, 170—1.
27.
Petricoin, E.F., III , Ornstein, D.K., Paweletz, C.P., Ardekani , A., Hackett, P.S., Hitt, B.A., Velassco, A., Trucco, C., Wiegand, L., Wood, K., Simone, C.B., Levine, P.J., Linehan, W.M., Emmert-Buck, M.R., Steinberg, S.M., Kohn, E.C., and Liotta, L.A. (2002c). Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst94(20), 1576—8.
28.
Tirumalai, R.S., Chan, K.C., Prieto, D.A., Issaq, H.J., Conrads, T.P., and Veenstra, T.D. (2003). Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics2(10), 1096—103. [Epub 2003 Aug 13].
29.
Tou, J. T., and Gonzalez, R., eds. (1974). Pattern Classification by Distance Functions. In Pattern Recognition Principles, Reodina MA: Addison Weley Publishing Comapny . New York.
30.
Ward, J.B. Jr., and Henderson, R.E. (1996). Identification of needs in biomarker research . Environ Health Perspect104(Suppl. 5), 895—900.
31.
Zhang, J., Herman, E.H., and Ferrans, V.J. (1993). Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187. Am J Pathol142(6), 1916—26.
32.
Zhang, J., Herman, E.H., Knapton, A., Chadwick, D.P., Whitehurst, V.E., Koerner, J.E., Papoian, T., Ferrans, V.J., and Sistare, F.D. (2002). SK&F 95654-Induced acute cardiovascular toxicity in Sprague-Dawley rats— histopathologic, electron microscopic, and immunohistochemical studies. Toxicol Pathol30(1), 28—40.
